CARACO PHARMACEUTICAL LABORATORIES LTD PRE 14A, filed Sep 23, 2009: CARACO PHARMACEUTICAL LABORATORIES PRE 14A 10-26-2009
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14A
(RULE
14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE
14A INFORMATION
PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF
1934
Filed by
the registrant ⌧
Filed by
a party other than the registrant □
Check the
appropriate box:
|
⌧ Preliminary
proxy statement
|
□ Confidential,
for use of the Commission only (as permitted by Rule 14a-6 (e)
(2)).
|
□ Definitive
proxy statement
□ Definitive
additional materials
□ Soliciting
material pursuant to Rule 14a-12
|
CARACO PHARMACEUTICAL LABORATORIES, LTD
|
|
(Name
of Registrant as Specified in Its Charter)
|
|
(Name
of Person(s) Filing Proxy Statement if Other Than the
Registrant)
|
Payment
of filing fee (check the appropriate box):
|
⌧
|
No
fee required
|
|
□
|
Fee
computed on table below per Exchange Act Rules 14a-6(i) (1) and
0-11.
|
|
|
(a)
|
Title
of each class of securities to which transaction
applies:
|
N/A
|
|
(b)
|
Aggregate
number of securities to which transactions
applies:
|
N/A
|
|
(c)
|
Per
unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was
determined):
|
N/A
|
|
(d)
|
Proposed
maximum aggregate value of
transaction:
|
N/A
|
|
(e)
|
Total
fee paid:
|
N/A
|
□
|
Fee
paid previously with preliminary
materials.
|
|
□
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a) (2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration
statement number, or the form or schedule and the date of its
filing.
|
|
|
(a)
|
Amount
Previously Paid:
|
N/A
|
|
(b)
|
Form,
Schedule or Registration Statement
No.:
|
N/A
|
|
(c)
|
Filing
Party:
|
N/A
|
|
(d)
|
Date
Filed:
|
N/A
CARACO
PHARMACEUTICAL LABORATORIES, LTD.
NOTICE
OF
SPECIAL
MEETING OF SHAREHOLDERS
AND
PROXY
STATEMENT
2009
CARACO
PHARMACEUTICAL LABORATORIES, LTD.
1150
Elijah McCoy Drive
Detroit,
Michigan 48202
NOTICE
OF SPECIAL MEETING OF SHAREHOLDERS
AND
PROXY
STATEMENT
2009
October
__, 2009
Dear
Shareholder,
We invite
you to attend our 2009 Special Meeting of Shareholders at 11:00 a.m., Eastern
Daylight Saving Time, on October 26, 2009 at the executive offices of the
Company at 1150 Elijah McCoy Drive, Detroit Michigan 48202.
Whether
or not you plan to attend the Meeting, please complete and mail the enclosed
proxy card promptly so that your shares will be voted as you desire. IF YOU WISH TO VOTE IN
THE MANNER THE BOARD OF DIRECTORS RECOMMENDS, IT IS NOT NECESSARY TO SPECIFY
YOUR CHOICES ON THE PROXY CARD. SIMPLY SIGN, DATE AND RETURN THE PROXY
CARD.
|
Sincerely,
Jitendra
N. Doshi
Chief
Executive Officer
|
CARACO
PHARMACEUTICAL LABORATORIES, LTD.
NOTICE
OF SPECIAL MEETING OF SHAREHOLDERS
|
Date:
|
October
26, 2009
|
|
Time:
|
11:00
a.m., Eastern Daylight Saving Time
|
|
Place:
|
Caraco
Pharmaceutical Laboratories, Ltd.
|
1150
Elijah McCoy Drive
Detroit,
Michigan 48202
We invite
you to attend the Caraco Pharmaceutical Laboratories, Ltd. Special Meeting of
Shareholders to:
|
|
1.
|
Approve
the amendment to Article VI, paragraph 4 of the Company’s Amended and
Restated Articles of Incorporation to permit vacancies on the Board of
Directors to also be filled by a vote of the Company’s
shareholders.
|
|
|
2.
|
Ratify
and elect one director for a term expiring in 2012 and upon the election
and qualification of his successor.
|
|
|
3.
|
Transact
any other business that is properly submitted before the Special
Meeting or any adjournment(s) of the
Meeting.
|
The
record date for the Meeting is September 21, 2009 (the “Record Date”). Only
shareholders of record at the close of business on that date can vote at the
Special Meeting. Caraco is mailing this Notice of Annual Meeting to those
shareholders.
A proxy
statement and proxy card are enclosed with this Notice. Whether or not you plan
to attend the Meeting and whether you own a few or many shares of stock, the
Board of Directors urges you to vote promptly. You may vote by signing, dating
and returning the enclosed proxy card.
A list of
shareholders who can vote at the Special Meeting will be available for
inspection by shareholders at the Meeting and for ten days prior to the Meeting
during regular business hours at the offices of Caraco, 1150 Elijah McCoy Drive,
Detroit, MI 48202.
|
By
Order of the Board of Directors,
Jitendra
N. Doshi
Chief
Executive Officer
|
October
__, 2009
Important
Notice Regarding the Availability of Proxy Materials for Special Meeting of
Shareholders to Be Held on October 26, 2009.
This
Notice of Special Meeting of Shareholders and Proxy Statement are available at
https://materials.proxyvote.com/14075T.
You may
obtain directions to the special meeting by sending a written request to Caraco
Pharmaceutical Laboratories, Ltd., Attention: Director, Human
Resources, 1150 Elijah McCoy Drive, Detroit, Michigan 48202.
TABLE OF CONTENTS
|
1
|
|
|
3
|
|
|
4
|
|
|
6
|
|
|
8
|
|
|
9
|
|
|
10
|
|
|
10
|
|
|
12
|
|
|
12
|
|
|
20
|
|
|
21
|
|
| A-1 |
CARACO PHARMACEUTICAL LABORATORIES, LTD.
1150
Elijah McCoy Drive
Detroit,
Michigan 48202
SPECIAL MEETING OF SHAREHOLDERS
2009
PROXY STATEMENT
QUESTIONS
AND ANSWERS
|
1.
|
Q:
|
What
is a proxy?
|
|
A:
|
A
proxy is a document, also referred to as a proxy card (which is enclosed),
by which you authorize someone else to vote for you in the way that you
want to vote. Caraco’s Board of Directors is soliciting this proxy. You
may also abstain from voting.
|
|
|
2.
|
Q:
|
What
is a proxy statement?
|
|
A:
|
A
proxy statement is the document the United States Securities and Exchange
Commission (the “SEC”) requires to explain the matters on which you are
asked to vote on the proxy card. Caraco’s proxy statement, together with
its enclosed proxy card, was first mailed to shareholders on or about
October __, 2009.
|
|
|
3.
|
Q:
|
Who
can vote?
|
|
A:
|
Only
holders of Caraco’s common stock at the close of business on September 21,
2009, the Record Date, can vote at the Special Meeting. Each shareholder
of record has one vote for each share of common stock on each matter
presented for a vote at the Meeting.
|
|
|
4.
|
Q:
|
How
do I vote if my stock is held in “street name?”
|
|
A:
|
If
your Caraco common stock is held in a brokerage account or by a bank or
other nominee, you are considered the beneficial owner of stock held in
“street name.” As a beneficial owner, you do not have the right to vote
your stock. Only the “record holder” of the stock has such rights. If you
wish to vote your stock, you should either (i) obtain a legal proxy from
the record holder of the stock appointing you as its legal proxy or (ii)
instruct the record holder how you would like the record holder to vote
the stock you own.
|
|
|
5.
|
Q:
|
What
will I vote on at the Meeting?
|
|
A:
|
At
the Special Meeting, shareholders will vote to:
|
|
|
1.
Approve the amendment to Article VI, paragraph 4 of the Company’s Amended
and Restated Articles of Incorporation to permit vacancies on the Board of
Directors to also be filled by a vote of the Company’s
shareholders.
|
||
|
2.
Ratify and elect one director for a term
expiring in 2012 and upon the election and qualification of his
successor.
|
||
|
3.
Transact any other business that is properly submitted
before the Special Meeting or any adjournment(s) of the
Meeting.
|
||
|
6.
|
Q:
|
Who
can attend the Special Meeting?
|
|
A:
|
You
are entitled to attend the Special Meeting only if you were a Caraco
shareholder as of the Record Date or you hold a valid proxy for the
special meeting. You should be prepared to present valid government-issued
photo identification for admittance. In addition, if you are a shareholder
of record, your name will be verified against the list of shareholders of
record on the Record Date prior to your being admitted to the Special
Meeting. If you are not a shareholder of record but hold shares through a
broker or nominee (i.e., in street name), you should provide proof of
beneficial ownership on the Record Date, such as your most recent account
statement, a copy of the voting instruction card provided by your broker,
trustee or nominee, or other similar evidence of ownership. If you do not
provide valid government-issued photo identification or comply with the
other procedures outlined above upon request, you may not be admitted to
the Special Meeting.
|
|
|
The
Meeting will begin promptly at 11:00 a.m., local time. Check-in will begin
at 10:30 a.m., and you should allow ample time for the check-in
procedures.
|
|
7.
|
Q:
|
How
does the Board of Directors recommend I vote on the
proposals?
|
|
A:
|
The
Board of Directors recommends a vote “FOR” the approval of
the amendment to Article VI, paragraph 4 of the Amended and Restated
Articles of Incorporation of the Company and “FOR” the Director
listed in Proposal 2.
|
|
|
8.
|
Q:
|
How
can I vote?
|
|
A:
|
You
can vote in person or by proxy. To vote by proxy, sign, date and return
the enclosed proxy card. If you return your signed proxy card to American
Stock Transfer before the Special Meeting, the persons named as proxies on
the card will vote your shares as you directed. You may revoke a proxy at
any time before the proxy is exercised by:
|
|
|
1.
|
giving
written notice of revocation to Donna Griffith, Director, Human Resources,
of Caraco, at 1150 Elijah McCoy Drive, Detroit, Michigan
48202;
|
|
|
2.
|
submitting
another proxy that is properly signed and later dated;
|
|
|
3.
|
voting
in person at the Meeting (but only if the shares are registered in
Caraco’s records in the name of the shareholder and not in the name of a
broker, dealer, bank or other third party).
|
|
|
9.
|
Q:
|
What
is a quorum?
|
|
A:
|
There
were 39,090,194 shares of Caraco’s common stock outstanding on the Record
Date. A majority of the outstanding shares, or 19,545,098 shares, present
or represented by proxy, constitutes a quorum. For purposes of a quorum,
abstentions and broker non-votes are included. A broker non-vote is a
proxy a broker submits that does not indicate a vote for some or all the
proposals because the broker does not have discretionary voting authority
and the broker did not receive instructions as to how to vote on those
proposals. A broker non-vote may also occur if your broker
fails to vote your shares for any reason. A quorum must exist
to conduct business at the Special Meeting.
|
|
|
10.
|
Q:
|
How
does voting work?
|
|
A:
|
If
a quorum exists, Proposal 1, the amendment to Article VI, paragraph 4 of
the Amended and Restated Articles of Incorporation, must receive the
approval of sixty-six and two-thirds percent (66 2/3%) of the outstanding
shares of the Company. Proposal 2, the ratification and
election of the Director, must receive the favorable vote of a majority of
the shares voted, present in person or represented by proxy, but excluding
broker non-votes and abstentions.
|
|
|
Caraco
will vote properly executed Proxies it receives prior to or at the Meeting
in the way you direct. If
you sign the proxy card but do not specify instructions, the shares
represented by Proxies will be voted “FOR” the amendment to
Article VI, paragraph 4 of the Amended and Restated Articles of
Incorporation and “FOR”
the Director. No other matters are currently
scheduled to be presented at the Meeting. If any matter or matters are
properly brought before the Meeting or any adjournment thereof, it is the
intention of the persons named in the accompanying proxy card to vote the
shares represented by the proxy card as they determine.
|
||
|
11.
|
Q:
|
Who
pays for the costs of the Meeting?
|
|
A:
|
Caraco
pays the cost of preparing and printing the proxy statement and soliciting
proxies. Caraco will solicit proxies primarily by mail, but may also
solicit proxies personally and by telephone. Caraco will reimburse banks,
brokerage houses and other custodians, nominees and fiduciaries for their
out-of-pocket expenses for forwarding solicitation material to beneficial
owners of Caraco’s common stock.
|
|
|
12.
|
Q:
|
When
are shareholder proposals for the 2010 Annual Meeting
due?
|
|
A:
|
All
shareholder proposals to be considered for inclusion in next year’s proxy
statement for the annual meeting must be submitted in writing to the
Secretary or Assistant Secretary of Caraco Pharmaceutical Laboratories,
Ltd., 1150 Elijah McCoy Drive, Detroit, Michigan 48202, before April 9,
2010.
|
|
|
13.
|
Q:
|
How
may a shareholder communicate with the Board of
Directors?
|
|
A:
|
Shareholders
may communicate with the Board of Directors or any member of the Board of
Directors by sending a letter addressed to the Board of Directors, c/o
Donna Griffith, Director, Human Resources, at 1150 Elijah McCoy Drive,
Detroit, Michigan 48202. The Board of Directors’ policy is to have all
shareholder communications compiled by the Director, Human Resources and
forwarded directly to the Board or the director as indicated in the
letter. All letters will be forwarded to the appropriate party. The Board
of Directors reserves the right to revise this policy in the event that
this process is abused, becomes unworkable or otherwise does not
efficiently serve the purpose of the
policy.
|
PROPOSAL 1 – AMENDMENT TO AMENDED AND RESTATED ARTICLES OF
INCORPORATION
Board
Authorization
On
September 9, 2009, our Board of Directors authorized an amendment to our Amended
and Restated Articles of Incorporation (the “Amendment”), subject to shareholder
approval, to revise Article VI paragraph 4, of the Company’s Amended and
Restated Articles of Incorporation to provide that vacancies in the Board of
Directors may also be filled by a majority vote of shares of common stock of the
Company present in person or represented by proxy. Specifically, Article VI,
paragraph 4 of the Amended and Restated Articles of Incorporation is proposed to
be revised as follows (marked from the current Article VI, paragraph 4 by
showing deletions in brackets and additions in bold and
underlined):
|
“4. Subject
to the rights of the holders of any series of Preferred Shares then
outstanding, newly created directorships resulting from any increase in
the authorized number of directors and any vacancies on the Board
resulting from death, resignation, retirement, disqualification, removal
from office or other cause shall be filled [only] by a majority vote of
the remaining directors then in office,
though less than a quorum, and/or
by a vote to ratify or elect by a majority of the shares present in person
or represented by proxy and voting on such ratification or
election, and directors so chosen shall hold office for a term
expiring at the annual meeting of shareholders at which the term of office
of the class to which they have been elected expires or until their
successors have been duly elected and qualified. No decrease in
the number of directors constituting the Board shall shorten the term of
any incumbent director.” |
Shareholder
Approval
Under our
Amended and Restated Articles of Incorporation, amendments to Article VI of the
Amended and Restated Articles of Incorporation require the affirmative vote of
the holders of at least sixty-six and two-thirds percent (66 2/3%) of the voting
power of all then outstanding shares of the Company’s common stock entitled to
vote in the election of Directors. Accordingly, the Amendment will
pass if it receives the favorable vote of 26,060,130 shares of the Company’s
common stock. Sun Pharmaceutical Industries Limited (“Sun Pharma”)
and its affiliates own, in the aggregate, 29,380,680 shares of the Company’s
common stock and have indicated that they intend to vote “For” Proposal
1.
Reasons
for the Amendment
As
discussed below, the Company examined Article VI, paragraph 4 and noted that it
provides that only the Board may fill vacancies on the Board of
Directors. For purposes of good corporate governance, and for
the reasons explained below, the Board believes that it is appropriate to also
provide that shareholders have the right to ratify and elect Directors to fill
vacancies on the Board.
On August
27, 2009, the Company received a shareholder demand letter demanding that the
Company take action against certain officers and Directors of the Company to
recover certain damages caused by their alleged breach of fiduciary duties by
“knowingly causing or allowing Caraco to manufacture products in violation of
the FDA’s GMP requirements, even after the FDA warned the Company about such
deficiencies.” The demand letter also requests that the Board
“correct the deficiencies in the Company’s internal controls that allowed the
misconduct to occur.” At the time of receipt of such letter, all of
the Directors on the Board of Directors, except for Jitendra N. Doshi, were
named as allegedly having breached their fiduciary duties. The demand
letter further provides that if the Board has not commenced an action as
demanded, the shareholder making the demand will commence a shareholder
derivative proceeding on behalf of the Company seeking appropriate
relief. Among other things, under Michigan law, a shareholder may not
commence a derivative proceeding unless 90 days have expired from the date the
demand was made.
Under
Michigan law, a court shall dismiss a derivative proceeding if upon motion of a
corporation, the court finds that one or more specified groups has made a
determination in good faith after conducting a reasonable investigation upon
which its conclusions are based that the maintenance of the derivative
proceeding is not in the best interests of the corporation. Certain
of the groups specified include disinterested
directors. Disinterested directors are defined under Michigan law,
with respect to derivative proceedings, as directors who are not parties to a
derivative proceeding. Since substantially all of the Directors of
the Company have been named in the demand letter as potential parties to the
derivative proceeding, none of them are disinterested except for Jitendra N.
Doshi and F. Folsom Bell. The other groups specified under Michigan
law include a panel of one or more disinterested persons appointed by a court or
all disinterested ‘independent’ directors. Under Michigan law, in
order to be “independent,” among other criteria, a director must be elected by
shareholders. As noted above, currently, Article VI, paragraph 4 of
our Amended and Restated Articles of Incorporation only permits the Board to
fill vacancies on our Board of Directors. We are asking for the
shareholders vote to amend Article VI, paragraph 4 in order to permit
shareholders to also ratify and elect Directors to fill vacancies on the Board
of Directors so that Mr. Bell who was recently appointed by the Board to
fill the vacancy on The Board following the 2009 Annual Meeting of Shareholders,
can be ratified and elected by shareholders at this special meeting (see
Proposal 2) and thereby be able to make a determination in good faith after
conducting a reasonable investigation upon which his conclusions are based as to
whether or not the maintenance of a derivative proceeding requested by the
shareholder demand letter is in the best interests of the
Company.
Effective
Date
The
effective date of the Amendment is intended to be on the date of the special
meeting, immediately following the shareholder vote on the Amendment, at which
time the Amendment will be filed with the Michigan Department of Energy, Labor
& Economic Growth, Bureau of Commercial Services – Corporation
Division.
Recommendation
A copy of
the proposed Amendment is included as Appendix “A” to this proxy
statement.
The
Board of Directors recommends a vote “FOR” the approval of the
Amendment.
PROPOSAL 2 – RATIFICATION AND ELECTION OF DIRECTOR
General
Caraco’s
Board of Directors is divided into three classes with each class of directors
elected to a three-year term of office. At this special meeting,
shareholders are being asked to ratify the appointment by The Board of F. Folsom
Bell to fill the vacancy created by the decision by Dr. John D. Crissman not to
stand for re-election at the 2009 Annual Meeting of Shareholders. On
September 9, 2009, Caraco’s Board of Directors appointed F. Folsom Bell to fill
the vacancy created by Dr. Crissman’s decision not to stand for re-election, for
a term commencing immediately following the 2009 Annual Meeting of Stockholders
and ending following the 2012 Annual Meeting of Shareholders unless such
appointment is not ratified by shareholders, and if shareholders do not
so ratify and elect Mr. Bell, his appointment will terminate immediately
following such vote. Proposal 2 must receive the favorable vote of a
majority of the shares voted, present in person or represented by proxy, but
excluding broker non-votes and abstentions. Sun Pharma and its
affiliates, which own 29,380,680 or 75.2% of the outstanding shares of common
stock, have indicated that they intend to vote “For” Proposal
2. Proposal 2 will be presented for vote at the special meeting
only if Proposal 1 is approved (see above).
If Mr.
Bell is unable or decides not to stand for ratification and election, the
proxies may vote the shares to elect any substitute nominee recommended by
the Board of Directors.
Caraco’s Board of Directors
recommends a vote “FOR” the
ratification and election of Mr. Bell.
RATIFICATION
AND ELECTION OF DIRECTOR FOR TERM EXPIRING 2012
|
Director
|
Age
|
Principal Occupation and Business Experience
During Past 5 Years and other Directorships
|
Director Since
|
|||
|
F.
Folsom Bell
|
67
|
Mr.
Bell has been a consultant on M&A transactions and involved in real
estate development since 2006. From September 2000 to December
2005, Mr. Bell was the Executive Vice-President, Business Development of
Perrigo Company, a global healthcare supplier that develops, manufactures
and distributes over-the-counter and generic prescription pharmaceuticals,
nutritional products,
active pharmaceutical ingredients and pharmaceutical and medical
diagnostic products. Mr. Bell was also a member of the board of
directors of Perrigo Company from January 1981 through February 1986
and from June 1988 to January 2003. While a director of
Perrigo Company,
Mr. Bell served for six years on its audit committee, including time as
chairman. Mr. Bell was a certified public accountant for
fifteen years with two major public accounting firms.
|
2009
|
DIRECTORS’
TERMS EXPIRING 2012
|
Directors
|
Age
|
Principal Occupation and Business Experience
During Past 5 Years and other Directorships
|
Director Since
|
|||
|
Dilip
S. Shanghvi
|
53
|
Mr.
Shanghvi has served as Chairman of the Board of Directors of Caraco since
1997. Mr. Shanghvi is the founder of Sun Pharmaceutical Industries Limited
(“Sun Pharma”), its Managing Director since its inception in 1993,
responsible for marketing, research and development and human resource
development, and its Chairman since 1999. Also, since March 2007 Mr.
Shanghvi has been the Chairman and Managing Director of Sun Pharma
Advanced Research Company Ltd. Mr. Valia is Mr. Shanghvi’s
brother-in-law.
|
1997
|
|||
|
Gurpartap
Singh Sachdeva
|
40
|
Mr.
Singh currently serves as Senior Vice President – Business Strategies
(since July 2007); previously Vice President – Sales and Marketing
(September 2003 to July 2007) and National Sales and Marketing Manager
(September 2000 to September 2003). From May 1998 to September
2000, Mr. Singh was the Manager of Bulk Drugs for Sun
Pharma.
|
2008
|
DIRECTORS’
TERMS EXPIRING 2011
|
Directors
|
Age
|
Principal Occupation and Business Experience
During Past 5 Years and other Directorships
|
Director Since
|
|||
|
Jitendra
N. Doshi
|
59
|
Mr.
Doshi has been appointed as Caraco’s interim Chief Executive Officer
effective July 2009. From 2006 to July 2009, he served as the
Executive Director of Sun Pharmaceutical Industries, Inc., a generic
pharmaceutical company and wholly-owned subsidiary of Sun Pharma. Mr.
Doshi has served Caraco in the following positions: Chief
Financial Officer (November 2002 to January 2007), Chief Operating Officer
(November 2002 to January 2007), interim Chief Executive Officer
(September 2003 to May 2005) and Senior Vice President-Commercial (April
2001 to November 2002). From September 1999 to April 2001, Mr.
Doshi was employed by Sun Pharma as General Manager – Operations. From
1991 to 1999, Mr. Doshi was Managing Director of Aqua Bearing Ltd., an
auto parts manufacturer organized under the laws of the Commonwealth of
India.
|
2009
|
|||
|
Sailesh
T. Desai
|
55
|
Mr.
Desai has served as a full-time director of Sun Pharma since 1999,
responsible for domestic marketing of some of the divisions dealing in
specific therapy segments of pharmaceutical formulations. From 1994 to
1998, Mr. Desai was the principal shareholder and Managing Director of
Milmet Laboratories, Pvt. Ltd., a manufacturer and marketer of ophthalmic
solutions which was organized under the laws of the Commonwealth of India
and merged into Sun Pharma in 1998.
|
2000
|
DIRECTORS’
TERMS EXPIRING 2010
|
Directors
|
Age
|
Principal
Occupation and Business Experience During Past 5 Years and other
Directorships
|
Director
Since
|
|||
|
Timothy
S. Manney
|
50
|
Since
May 2002, Mr. Manney has been President and Director of Synova, Inc. (a
privately-held information technology staffing and creative–services
consulting firm). From 1990 to 2001, Mr. Manney served as the Chief
Financial Officer of Covansys Corporation (a publicly-held information
technology solutions company).
|
2004
|
|||
|
Madhava
Reddy
|
51
|
Mr.
Reddy is President and Chief Executive Officer of HTC Global Services,
Inc., a private Michigan corporation he organized in 1992. HTC Global
Services is a global information and technology service and solution
provider. HTC Global Services currently has offices in Australia, Canada,
India, Malaysia, Singapore, and the United Kingdom, and has its corporate
offices in Troy, Michigan.
|
2005
|
|||
|
Sudhir
V. Valia
|
53
|
Mr.
Valia joined Sun Pharma as a director in January 1994 and has been a
full-time director since his appointment in April 1994. He is
currently responsible for finance, commercial, operations, projects and
quality control. Prior to then, Mr. Valia was a chartered
accountant in private practice. Mr. Valia is a qualified chartered
accountant in India. Mr. Shanghvi is Mr. Valia’s
brother-in-law.
|
1997
|
BOARD OF DIRECTORS AND ITS COMMITTEES
Board
of Directors
During
Fiscal 2009, the Board of Directors met five times. All of the then
directors attended at least 75% of the meetings of the Board and the committees
on which they served during Fiscal 2009, except for Messrs. Desai, Reddy, and
Valia. The Board of Directors encourages Board members to attend each
Annual Meeting of Shareholders. At the 2008 Annual Meeting of Shareholders,
three of the current
Caraco directors were in attendance. At the 2009 Annual Meeting of Shareholders,
five of the current Caraco directors were in attendance. In addition
to meetings, the Board and the committees take corporate action through
unanimous written consents.
The Board
of Directors is fixed at eight members. The Board has determined that
Messrs. Bell, Manney and Reddy are “independent” directors within the meaning of
Section 803A of the NYSE Amex Company Guide (“NYSE Amex Company
Guide”). Unless a company is a “controlled company” under the NYSE Amex Company
Guide, a majority of its Board of Directors must be independent. As a result of
Sun Pharma and its affiliates owning a majority of the outstanding voting
shares, Caraco is a controlled company under NYSE Amex Company Guide and is
therefore not required (i) to have a majority of independent directors on its
Board;(ii) to have the compensation of the Chief Executive Officer and all other
officers determined or recommended to the Board either by the Compensation
Committee comprised of independent directors or by a majority of the independent
directors, and (iii) to have nominations to the Board of Directors either
selected, or recommended for the Board’s selection, by either a nominating
committee comprised solely of independent directors or by a majority of the
independent directors.
Committees
of the Board
The Board
maintains three standing committees: audit, compensation and independent. These
are described below.
Audit
Committee. The Audit Committee is responsible for selecting, evaluating,
retaining and, where appropriate, replacing Caraco’s independent auditors.
Generally, the Audit Committee monitors the integrity of Caraco’s financial
statements and the independence and qualifications of the independent auditors.
The Audit Committee is governed by a written charter. The Audit Committee’s
responsibilities are described in more detail in such charter. A copy of the
charter was included as Appendix A to the proxy statement for the 2009 Annual
Meeting of Shareholders. The Audit Committee has been established in
accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934, as
amended. The Audit Committee held five meetings in Fiscal 2009. The
current members of the Audit Committee are Messrs. Bell, Manney and
Reddy. Mr. Manney is the committee’s Chairman. The Board has
determined that each of these members is independent under Section 803A and 803B
of the NYSE Amex Company Guide. The Board has also determined each of the
committee members is able to read and understand fundamental financial
statements, including a company’s balance sheet, income statement and cash flow
statement. In addition, the Board of Directors has determined that Mr. Manney is
an audit committee financial expert. Mr. Bell was appointed to the Audit
Committee on September 21, 2009.
Compensation
Committee. The Compensation Committee oversees Caraco’s policies and
programs for the compensation of its officers. The Committee determines the
compensation of our Chief Executive Officer and delegates to him the
responsibility to determine the base salaries and bonuses of all officers other
than the Chief Executive Officer, under the constraints of an overall limitation
on the total amount of compensation to be paid to them. The Compensation
Committee is also responsible for the review and approval of compensation
programs for officers and employees, including fringe benefits and stock options
and/or bonuses, as may be from time to time recommended by management. Grants of
options or other equity awards are made by the two “non-employee directors” as
defined by 16b-3 who are also “outside directors” for purposes of Section 162(m)
of the Internal Revenue Code. The Compensation Committee held four meetings
during Fiscal 2009. The Compensation Committee currently consists of
Messrs. Shanghvi, Bell and Manney. Mr. Shanghvi serves as the
Chairman. Mr. Bell was appointed to the Compensation Committee on September 21,
2009.
Independent
Committee. The Independent Committee was established to negotiate a
products agreement between Caraco and Sun Pharma Global, Inc. (“Sun Global”), a
wholly-owned subsidiary of Sun Pharma. In 2005, the Board of Directors ratified
and approved the authority of the Independent Committee (with respect to past,
present and future actions) to review and approve all related party
transactions. The Independent Committee held three meetings during
Fiscal 2009. The Independent Committee currently consists of Messrs.
Bell, Manney, and Reddy. The Board has determined that all of the members are
independent under Section 803A of the NYSE Amex listing standards currently in
effect. Mr. Bell serves as the Chairman. Mr. Bell was appointed to
the Independent Committee on September 21, 2009.
Special
Litigation Committee. The Board has designated Mr. Bell
as ‘independent’ under Michigan law effective upon his ratification and election
by shareholders at this special meeting. As discussed under Proposal 1 above,
following such ratification and election, as an independent director, it is
intended that Mr. Bell will conduct a reasonable investigation into the
allegations made by a shareholder in a demand letter that certain officers and
directors have breached their fiduciary duties to the Company in connection with
the FDA action against the Company. Mr. Bell will then make a
determination in good faith after conducting such reasonable investigation upon
which his conclusions are based as to whether or not the maintenance of a
derivative proceeding requested by the shareholder demand letter is in the best
interests of the Company.
Nomination
of Directors
The Board
of Directors has not established a formal nominating committee as the entire
Board serves in this capacity. The Board of Directors has not maintained a
formal nominating committee because the Board of Directors feels that it is not
necessary since the size of the Board is relatively small. While the
Board has not established a formal committee, in the past the Board has asked
one or two of its directors to meet with a number of candidates and to make
recommendations to the full Board. The Board may utilize a variety of methods
for identifying potential nominees, including considering potential candidates
who come to their attention through current officers, directors, Caraco’s
professionals, professional search firms or other persons. Once a
potential nominee has been identified, the Board evaluates whether the nominee
has the appropriate skills and characteristics to become a director in light of
the then make-up of the Board of Directors. This assessment includes an
evaluation of the candidate’s judgment and skills, such as experience at a
policy setting level, financial sophistication, leadership and objectivity. At a
minimum, the Board of Directors believes that all members of the Board should
have the highest professional and personal ethics and values. Mr. F.
Folsom Bell was presented for consideration as a Director by the Chairman of the
Board, and appointed by the Board in September 2009, as disclosed above, to
fill the vacancy created by the decision by Dr. John D. Crissman not to stand
for re-election at the 2009 Annual Meeting of Shareholders.
The Board
of Directors considers stockholder nominations for candidates for membership on
the Board when properly submitted in accordance with Company’s bylaws. The
Company’s bylaws provide that nominations for the election of directors may be
made by any stockholder entitled to vote in the election of directors if timely
notice of such shareholder’s intent has been given in writing to the secretary
or an assistant secretary of the Company. To be timely, a shareholder’s notice
must be delivered to or mailed and received at the principal executive offices
of the Company not less than 120 calendar days before the date the Company’s
proxy statement is released to shareholders in connection with the previous
year’s annual meeting. Each such notice shall set forth (a) the name and address
of the shareholder who intends to make the nomination and of the person or
persons to be nominated; (b) a representation that the shareholder is a
shareholder of record of stock of the Company entitled to vote for the election
of directors on the date of such notice and intends to appear in person or by
proxy at the meeting to nominate the person or persons specified in the notice;
(c) a description of all arrangements or understandings between the shareholder
and each nominee and any other person or persons (naming such person or persons)
pursuant to which the nomination or nominations are to be made by the
shareholders; (d) such other information regarding each nominee proposed by such
shareholder as would be required to be included in a proxy statement filed
pursuant to the proxy rules of the SEC, had the nominee been nominated, or
intended to be nominated, by the Board of Directors; and (e) the consent of each
nominee to serve as a director of the Company if so elected.
Report
of the Audit Committee
The
information contained in this report shall not be deemed to be “soliciting
material” or “filed” with the SEC or subject to the liabilities of Section 18 of
the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), except
to the extent that we specifically incorporate it by reference into a document
filed under the Securities Act of 1933, as amended (the “Securities Act”) or the
Exchange Act.
Our
management is responsible for the preparation, presentation and integrity of our
financial statements, the accounting and financial reporting principles, and the
internal controls and procedures designed to assure compliance with accounting
standards and applicable laws and regulations. The independent auditors are
responsible for an integrated audit of our financial statements and internal
control over financial reporting. The integrated audit is designed to
express an opinion on our financial statements, an opinion on management’s
assessment of internal control over financial reporting and an opinion on the
effectiveness of internal control over financial reporting. The
Committee's responsibility is generally to monitor and oversee these
processes.
In the
performance of its oversight function, the Committee:
|
|
•
|
Met
to review and discuss our audited financial statements for the year ended
March 31, 2009 with our management and our independent
auditors;
|
|
|
•
|
Discussed
with the independent auditors the matters required to be discussed by
Statement on Auditing Standards No. 61, as amended (AICPA, Professional Standards,
Vol. 1, AU Section 380), as adopted by the Public Company Accounting
Oversight Board in Rule 3200T;
|
|
|
•
|
Received
the written disclosures and the letter from the independent auditors
required by applicable requirements of the Public Company Accounting
Oversight Board regarding the independent auditors communications with the
audit committee concerning independence, and discussed with the
independent auditors the independent auditors’
independence.
|
While the
Committee has the responsibilities and powers set forth in its charter, it is
not the duty of the Committee to plan or conduct audits or to determine that the
Company's financial statements are complete and accurate and in accordance with
generally accepted accounting principles. This is the responsibility of
management. The independent registered public accounting firm is responsible for
planning and conducting its audits.
Based
upon the review and discussions described in this report, and subject to the
limitations on the role and responsibilities of the Committee referred to above
and in its charter, the Committee recommended to the Board that the audited
financial statements be included in our Annual Report on Form 10-K for the year
ended March 31, 2009 for filing with the Securities and Exchange
Commission. Mr. Bell did not become a member of the Audit Committee
until his appointment on September 21, 2009. Mr. Georges Ugeux was a
member of the Audit Committee until his resignation on September 20,
2009.
|
The
Audit Committee
|
|
|
Timothy
S. Manney (Chairman)
|
|
|
Madhava
Reddy
|
Code
of Business Conduct and Ethics
The
Company has adopted a Code of Business Conduct and Ethics (the “Code”)
applicable to its directors, officers and employees. A copy of the Code is
available at no charge by contacting the Director, Human Resources, Donna
Griffith, at 1150 Elijah McCoy Drive, Detroit, MI 48202, or by telephone: (313)
871-8400 or by email: donna.griffith@caraco.com.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
The SEC
requires that Caraco provide information about any shareholder who beneficially
owns more than 5% of Caraco’s common stock. The following table provides the
required information, as of the Record Date, about the shareholders (who are not
officers or directors) known to Caraco to be the beneficial owners of more than
5% of Caraco’s common stock. Caraco relied solely on information furnished by
its transfer agent and Schedule 13Ds filed with the SEC.
|
Name
and Address of Beneficial Owner
|
Amount
and Nature of Beneficial Ownership
|
Percentage
of Class
|
||
|
Sun
Pharmaceutical Industries Limited
|
29,380,680(1)
|
75.2%(1)
|
||
| 17/B Mahal Industrial Estate | ||||
|
Mahakali
Caves Road
|
||||
|
Andheri
(East), Mumbai, 400 093 India
|
|
(1)
|
Sun
Pharmaceutical Industries Limited directly owns 8,382,666 shares of common
stock of Caraco and beneficially owns 20,998,014 shares registered in the
name of Sun Pharma Global Inc. (“Sun Global), its wholly-owned
subsidiary. Sun Global’s address is International Trust
Building, P.O. Box 659, Road Town, Tortola, British Virgin
Islands. In addition, Sun Global owns 1,088,000 shares of
Series B preferred stock which are convertible into 1,088,000 shares of
common stock three years from the date of their respective issuance or
upon a change in control. Including such Series B preferred
stock, Sun Pharma beneficially owns 75.8% of
Caraco.
|
SECURITY OWNERSHIP OF MANAGEMENT AND DIRECTORS
The
following table contains information, as of the Record Date, about the number of
shares of Caraco’s common stock beneficially owned by incumbent directors, the
executive officers and by all current directors, nominees and executive officers
as a group. The number of shares of common stock beneficially owned by each
individual includes shares of common stock which the individual can acquire by
November 20, 2009 through the exercise of any stock option or other right.
Unless indicated otherwise, each individual has sole investment and voting power
(or shares those powers with his or her spouse) with respect to the shares of
common stock listed in the table.
|
Name of Beneficial Owner
|
Amount and Nature of Beneficial
Ownership
|
Percentage of Class
|
||||
|
Dilip
S. Shanghvi (1)
|
(2) | (2) | ||||
|
Jitendra
N. Doshi (3)
|
75,000 | (4) | * | |||
|
Mukul
Rathi (3)
|
4,333 | (5) | * | |||
|
Robert
Kurkiewicz (3)
|
8,679 | (6) | * | |||
|
Gurpartap
Singh Sachdeva (3)
|
16,800 | (7) | * | |||
|
F.
Folsom Bell(3)
|
0 | * | ||||
|
Sailesh
T. Desai (8)
|
(2) | (2) | ||||
|
Timothy
S. Manney (9)
|
17,500 | (10) | * | |||
|
Madhava
Reddy (11)
|
6,000 | (12) | * | |||
|
Sudhir
V. Valia (13)
|
(2) | * | ||||
|
All
executive officers and directors as a group (10
persons)
|
128,312 | (2) | (2) | |||
|
*
|
Less
than 1.0% of the outstanding shares
|
|
(1)
|
The
mailing address of Mr. Shanghvi is c/o Sun Pharmaceutical Industries
Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (E)
Bombay 400 093 India.
|
|
(2)
|
Excludes
30,380,680 shares of common stock and 1,088,000 shares of Series B
preferred stock beneficially owned by Sun Pharma and Sun Global. (See
footnote 1 under “Security Ownership of Certain Beneficial Owners” and “Transactions of
Directors, Executive Officers and Certain Beneficial Holders of Caraco.”)
Mr. Shanghvi is the Chairman and Managing Director of, and Messrs. Desai,
and Valia are directors of, and Mr. Shanghvi, together with his associate
companies, is also the majority shareholder of, Sun Pharma, and,
therefore, may be deemed to share investment control over the shares of
common stock held by Sun Pharma and Sun Global. Each of Messrs.
Desai and Valia disclaims beneficial ownership of the shares of common
stock beneficially owned by Sun Pharma and Sun
Global.
|
|
(3)
|
The
mailing address of each of these holders is 1150 Elijah McCoy Drive,
Detroit, Michigan 48202.
|
|
(4)
|
Includes
26,500 shares held in the name of his
wife.
|
|
(5)
|
Includes
stock options that are currently exercisable to purchase 4,333 shares of
common stock.
|
|
(6)
|
Includes
stock options that are currently exercisable to purchase 1,666 shares of
common stock.
|
|
(7)
|
Includes
1,800 shares held in the name of his wife and stock options that are
currently exercisable to purchase 5,000 shares of common
stock.
|
|
(8)
|
Mr.
Desai’s mailing address is c/o Sun Pharmaceutical Industries Limited, Acme
Plaza, Andheri-Kurla Road, Bombay 400 059
India.
|
|
(9)
|
Mr.
Manney’s mailing address is c/o Synova, Inc., 1000 Town Center, Suite 700,
Southfield, Michigan 48075.
|
|
(10)
|
Includes
stock options that are currently exercisable to purchase 7,500 shares of
common stock.
|
|
(11)
|
Mr.
Reddy’s mailing address is c/o HTC Global Services, Inc., 3270 West Big
Beaver Road, Troy, Michigan 48084.
|
|
(12)
|
Includes
stock options that are currently exercisable to purchase 3,500 shares of
common stock.
|
|
(13)
|
Mr.
Valia’s mailing address is c/o Sun Pharmaceutical Industries Limited, Acme
Plaza, Andheri-Kurla Road, Andheri (East), Bombay 400 059
India.
|
Equity
Compensation Plan Information
3-31-09
|
Plan category
|
Number
of securities to be issued upon exercise of outstanding options, warrants and rights.
|
Weighted-average
exercise price of outstanding options, warrants and rights.
|
Number
of securities remaining available for future issuance under equity
compensation plans (excluding securities reflected in first column)
|
|||||||||
|
Equity
compensation plans approved by security holders
|
227,000 | $ | 11.81 | 988,000 | ||||||||
|
Equity
compensation plans not approved by security holders
|
200,000 | $ | 3.50 | 0 | ||||||||
|
(see
discussion below)
|
||||||||||||
|
Total
|
427,000 | $ | 7.92 | 988,000 | ||||||||
The
equity compensation plans approved by security holders consists of the 2008
Equity Participation Plan and the 1999 Equity Participation Plan (the
“Plans”). The above referenced options under the Plans were granted
to employees, officers and directors. The equity compensation plans not approved
by security holders consist of options granted to an unaffiliated generic drug
company with respect to sign-up options for products. With respect to
the formula for one product, the Company has determined it is different from the
formula approved by the FDA and manufactured and introduced by the
Company.
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section
16(a) of the Securities Exchange Act of 1934 requires that Caraco’s directors,
executive officers and persons who own more than ten percent of a registered
class of Caraco’s
equity securities file reports of stock ownership and any subsequent changes in
stock ownership with the SEC not later than specified deadlines. To
Caraco’s knowledge,
based solely on a review of the copies of such reports furnished to Caraco, all
directors, executive officers and persons who own more than ten percent of
Caraco’s equity
securities complied with applicable Section 16(a) filing requirements for Fiscal
2009, except as follows: Messrs. Kurkiewicz, Rathi and
Sachdeva each filed a late report with respect to one
transaction.
TRANSACTIONS OF DIRECTORS, EXECUTIVE OFFICERS AND CERTAIN BENEFICIAL
HOLDERS OF CARACO
The
following discloses transactions during Fiscal 2009, 2008 and 2007, and proposed
transactions between Caraco and several of the incumbent and nominee directors,
executive officers and security holders who beneficially hold in excess of five
percent of our outstanding shares:
On
November 21, 2002, we entered into a products agreement with Sun
Global. Under the agreement, which was approved by our independent
directors, Sun Global agreed to provide us with 25 new generic drugs over a
5-year period. In exchange for each new generic drug transferred to
us by Sun Global which passed bioequivalency studies, we issued Sun Global
544,000 shares of Series B preferred stock. During Fiscal 2008 and
2007, Sun Global earned 10,088,000 and 1,632,000 shares of Series B preferred
stock for two product transfers and three product transfers, respectively, as
provided under the November 2002 products agreement. Sun Global has
provided us with all 25 generic drugs all of which have passed their
bioequivalency studies through Fiscal 2008. The products agreement
was completed in Fiscal 2008 and all shares of Series B preferred stock were
issued to Sun Global under the agreement.
During
Fiscal 2009, 2008 and 2007, we purchased approximately $8.4 million, $498.5
million and $38.8 million, respectively, of our raw materials and finished goods
formulations from Sun Pharma. We intend to continue to purchase raw
materials and formulations from Sun Pharma in Fiscal 2010.
During
Fiscal 2009, 2008 and 2007, Caraco purchased at Sun Pharma and its affiliates’
cost, approximately $46 thousand, $0.3 million and $0.8 million, respectively,
of machinery and equipment from Sun Pharma and its affiliates. We
intend to continue to purchase machinery and equipment from Sun Pharma and its
affiliates in Fiscal 2010.
Caraco
entered into a manufacturing and supply agreement and a distribution and sale
agreement in December 2004 with respect to one product with an affiliate of Sun
Pharma, Sun Pharmaceutical Industries, Inc. Caraco entered into
another distribution and sales agreement with Sun Pharmaceutical Industries,
Inc. in January 2005 with respect to another product.
In Fiscal
2007 Caraco entered into a three-year marketing agreement with Sun Pharma, which
was reviewed and approved by the Independent Committee. Under
the agreement, the Company purchases selected product formulations offered by
Sun Pharma, and
markets
and distributes them as part of its current product offerings in the U.S., its
territories and possessions, including Puerto Rico. Sun Pharma is not
obligated to offer Caraco Products under this Agreement, however, Caraco has the
exclusive right to market in the U.S., its territories and possessions,
including Puerto Rico, any products offered by Sun Pharma and accepted by
Caraco.
During
Fiscal 2008, the Corporation entered into a three-year distribution and sale
agreement with Sun Pharma, which was reviewed and approved by the Independent
Committee. Under this agreement, the Company purchases selected
formulations which have been filed under the Paragraph IV certification process
with the FDA by Sun Pharma and offered for distribution. Paragraph
IV (“Para IV) certified products may face litigation challenges with
respect to claims of patent infringement. Under the agreement, the
Company shares in the sales opportunity and shares the litigation
risks. The Company is indemnified by Sun Pharma of any risks beyond
the percentage agreed to as its profit percentage, thereby limiting the
Company’s exposure. Sun Pharma is not obligated to offer Caraco
products under this agreement, however, Caraco has the exclusive right to market
in the U.S., its territories and possessions, including Puerto Rico, any
products offered by Sun Pharma and accepted by Caraco. The Company
markets and distributes the same as part of its current product offerings in the
U.S., its territories and possessions, including Puerto Rico. The
license granted with respect to a product terminates upon the end of an
exclusivity period or 180 days or a non-appealable court decision, or until a
third generic manufacturer launches the product, whichever is later, or until a
settlement is reached, at which time the product will become part of the
standard Caraco-Sun Pharma marketing agreement disclosed above. The
Company currently receives a fixed margin of 8%, or such other percentages that
shall be mutually agreed upon. Under the agreement, Sun Pharma and
Caraco mutually indemnify each other, capped by the fixed margin percentage with
respect to damages from infringement.
The
Corporation has also obtained technical and scientific services, including
bio-equivalency studies, with respect to certain mutually agreed
upon products, from the Clinical Research Organization operated by Sun Pharma.
During Fiscal 2009, the Corporation incurred $0.3 million related to these
services. No fees for these services were incurred during Fiscal 2008 and Fiscal
2007.
During
Fiscal 2009, 2008 and 2007, the Company had net sales of $225.4 million, $225.1
million, and $4.6 million of the marketed products under the aforesaid
agreements, respectively.
During
Fiscal 2010, Caraco entered into an agreement with Alkaloida Chemical Company
ZRT, a Hungarian corporation (“Alkaloida”) and indirect subsidiary of Sun
Pharma, which was reviewed and approved by the Independent Committee, pursuant
to which Alkaloida will provide for certain products mutually agreed to an
exclusive, non-transferable license to Caraco to manufacture and market the
products in the United States, its territories and possessions, including Puerto
Rico. The license for a product is for a period of five (5) years from the
commencement of marketing of the product, however, Caraco may extend the license
for a further five (5) year period. Caraco is responsible, among other things,
for the costs of all product tests, including bioequivalency studies, and the
costs of manufacturing and marketing each product. Alkaloida shall receive
royalties on the net sales of each product
The
Independent Committee reviews related party transactions on the basis that they
shall not generally be less favorable in the aggregate than would be usual and
customary in similar transactions between unrelated parties dealing at arm’s
length.
EXECUTIVE OFFICERS
Jitendra
N. Doshi was appointed as interim Chief Executive Officer and as a Director of
the Company following the resignation of Daniel H. Movens as Chief Executive
Officer and Director effective at the close of business on July 28, 2009. The
following table provides current information about Caraco’s executive officers who are
not directors.
|
Name
|
Age
|
Five-Year Business
Experience
|
Executive Officer Since
|
|||
|
Mukul
Rathi
|
36
|
Interim
Chief Financial Officer (since January 2007); previously, Controller (from
December 2005 to July 2007). From May 1999 to December 2005, he
was Sr. Executive-Accounts and Manager-Accounts with Sun
Pharma. He also served as Officer-Accounts for Century Enka,
Ltd. from August 1997 to May 1999. Mr. Rathi
graduated from the University of Calcutta in India and
subsequently qualified to be a member of the Institute of Chartered
Accounts of India.
|
2007
|
|||
|
Robert
Kurkiewicz
|
58
|
Senior
Vice President – Regulatory (since October 2006); previously, Senior Vice
President – Technical (October 1998 to October 2006) and Vice President –
Quality Assurance (November 1993 to October 1998).
|
1993
|
COMPENSATION OF EXECUTIVE OFFICERS
Compensation
Discussion and Analysis
This
Compensation Discussion & Analysis (“CD&A”) outlines our
compensation philosophy, objectives and processes for our executive
officers. It explains how we make executive compensation decisions,
the data we use and the reasoning behind the decisions that we
make.
Following
the CD&A are tables and other information that explain the compensation for
our executive officers, including discussion of the potential compensation of
our executive officers following termination of employment under different
situations.
These
tables and narratives assist us in communicating our compensation plans to our
stockholders.
Compensation
Philosophy
Our
compensation philosophy extends to all employees, including executive officers,
and is designed to align employee and stockholder interests. The philosophy’s
objective is to pay fairly based upon the employee’s position, experience,
individual performance and Company performance. Employees may be
rewarded through additional compensation when the Company meets or exceeds
targeted business objectives. Generally, under our compensation philosophy, as
an employee’s level of responsibility increases, a greater portion of his or her
total potential compensation becomes contingent upon annual
performance.
The
principles of our compensation philosophy are described below:
|
|
•
|
Market-driven.
Compensation programs are structured to be competitive both in their
design and in the total compensation that they
offer.
|
|
|
•
|
Stockholder-aligned.
Certain full-time employees have some portion of their incentive
compensation aligned with our financial
performance.
|
|
|
•
|
Performance-based.
Certain full-time employees have some portion of their incentive
compensation linked to a combination of Company, departmental, and/or
individual performance. The application of performance measures as well as
the form of the reward may vary depending on the employee’s position and
responsibilities. A formal performance evaluation process is used to
objectively assess individual
performance.
|
Review
of Executive Officer Compensation
The
Compensation Committee (the “Committee” with respect to this section of the
proxy statement) determines the compensation of our Chief Executive Officer and
delegates to him the responsibility to determine the base salaries and bonuses
of all officers other than the Chief Executive Officer under the constraints of
an overall limitation on the total amount of compensation to be paid to
them.
Our
current policy is that the various elements of the compensation package are not
interrelated in that gains or losses from past equity incentives are not
factored into the determination of other compensation. For instance,
if options that are granted in a previous year become underwater the next year,
the Committee does not take that into consideration in determining the amount of
the bonus, options or restricted stock to be granted the next
year. Similarly, if the options or restricted shares granted in a
previous year become extremely valuable, the Committee does not take that into
consideration in determining the bonus, options or restricted stock to be
awarded for the next year. In addition, the amount of a cash bonus
does not affect the number of options or restricted stock that is granted during
a particular year. A subcommittee of the Committee, comprised of
independent directors, determines grants of options and stock to our executive
officers.
We have
no policy with regard to the adjustment or recovery of awards or payments if our
relevant performance measures upon which they are based are restated or
otherwise adjusted in a manner that would reduce the size of an award or
payment.
Components
of Compensation—Executive Officers
Our
executive officers are compensated through the following four
components:
|
|
•
|
Base
Salary
|
|
|
•
|
Annual
Incentive Compensation
|
|
|
•
|
Long-Term
Incentives (stock options and/or grants of
stock)
|
|
|
•
|
Benefits
|
These
components provide a balanced mix of base compensation and compensation that is
contingent upon each executive officer’s individual performance and Company
performance. A goal of the compensation program is to provide executive officers
with a reasonable level of security through base salary and benefits, while
rewarding them through incentive compensation to achieve business objectives and
create stockholder value. We want to ensure that our compensation programs are
appropriately designed to encourage executive officer retention and motivation
to create stockholder value.
Base
salaries, benefits and incentive compensation opportunities are generally
targeted between the median and 75th percentile of general survey market data
derived from indices covering these same components for generic pharmaceutical companies of various sizes. Included in this review were
direct competitor companies. The companies represented may have brand
segments within its business to complement its generic pharmaceutical segments.
Others within the group may solely be generic pharmaceutical
companies. The companies include Actavis Group, Barr Pharmaceuticals
Inc., Dr. Reddy’s Laboratories Limited, Endo Pharmaceuticals Holdings
Inc., Forest Laboratories, Inc., King Pharmaceuticals, Inc. Lannett Company,
Inc., Mylan Inc., Paddock Laboratories, Inc., Par Pharmaceutical Companies,
Inc., Sandoz, Inc.(a division of Novartis AG), Teva Pharmaceutical Industries
Limited, Watson Pharmaceuticals, Inc. and Wyeth. We have not
used third party consultants to provide us with recommendations or
reports. We have utilized the survey data to reach our target
compensation objectives.
Base
Salaries
Base
salaries are targeted to be competitive when compared to the salary levels of
persons holding similar positions in other pharmaceutical companies and other
publicly traded companies of comparable size. Each executive officer’s
respective responsibilities, experience, expertise and individual performance
are considered.
In Fiscal
2009, our Compensation Committee did not increase the base salary of our Chief
Executive Officer from the Fiscal 2008 base salary. Effective Fiscal
2009, the Chief Executive Officer, pursuant to delegated authority from the
Compensation Committee, increased the base salaries for Gurpartap Singh
Sachdeva, Senior Vice President – Business Strategies, Robert Kurkiewicz, Senior
Vice President – Regulatory and Mukul Rathi, interim Chief Financial Officer as
follows: Gurpartap Singh Sachdeva from $225,096 to $243,104; Robert
Kurkiewicz from $161,522 to $167,983 and Mukul Rathi from $88,400 to
$110,000. Other than the interim Chief Financial Officer who had his
based salary increased to $125,000 in June 2009, none of the other executive
officers have had their base salaries increased in Fiscal 2010.
Annual
Cash Bonus Recognition Program
Our
annual cash bonus recognition program is specifically designed to provide
at-risk and contingent cash awards based on the achievement of performance goals
which are linked directly to individual, business and strategy objectives for
each participant. This linkage, particularly when combined with a
market-based base salary program, provides our officers with a competitive level
of compensation when objectives are achieved.
Annual
Cash Bonus Recognition Award for our Chief Executive Officer
On an
annual basis, the Compensation Committee determines whether to award a cash
bonus to our Chief Executive Officer based on the Company's performance and his
individual performance contributions during the Fiscal
year. Annually, the targets and the percentages allocated to each are
determined by the Compensation Committee. However, the Compensation Committee
retains the discretion to change or eliminate the bonus award whether or not the
performance criteria are satisfied.
In Fiscal
2009, our Chief Executive Officer was eligible to receive a targeted cash bonus
of up to 50% of his base salary, or $214,968. The Fiscal 2009
performance parameters for the Chief Executive Officer (with the percentage of
targeted cash bonus included in parentheses) included:
|
|
●
|
achieving net sales target of $461 million
(15%);
|
|
|
●
|
maintaining
gross profit of 46% or above for manufactured products
(20%);
|
|
|
●
|
lowering
overall SG&A percentage excluding Sun related SG&A expenses
(15%);
|
|
|
●
|
increasing
product development filings (15%);
|
|
|
●
|
reducing
incidences by 50% (20%); and
|
|
|
●
|
increasing
productivity in quality and manufacturing
(15%).
|
As a
result of the Company’s overall performance, no cash bonus was awarded by the
Compensation Committee to the Chief Executive Officer.
Annual
Cash Bonus Recognition Awards for our Named Executive Officers other than our
Chief Executive Officer
Each
year, the Compensation Committee adopts a program, based on the recommendation
of our Chief Executive Officer, that provides specific achievement targets and
weighting of those achievements as part of the overall target
bonus. The attainment level of these goals is used to calculate the
annual cash bonus recognition portion of the total compensation of our executive
officers. The target bonus percentage is a standard percentage for
each position and that position's contribution to the overall operation of the
Company. However, the Compensation Committee retains the discretion to change or
eliminate the bonus award whether or not the performance criteria are
satisfied.
The
targets for each of such named executive officers for Fiscal 2009 (with the
percentage of targeted cash bonus included in parentheses) were as
follows:
|
|
●
|
Our
Interim Chief Financial Officer’s targeted 2009 bonus was up to 15% of his
base salary, predicated on the level of attainment of the following
targets: transition to monthly close of financials
(20%), achievement of the Company’s overall sales goals (25%),
improved reporting of accounts receivable activity on a periodic basis
with action steps and resolution time line (20%), improved costing
information and analysis (20%), and the balance (15%) based on individual
development goals and at the discretion of our Chief Executive
Officer.
|
|
|
●
|
Our
Senior Vice President - Business Strategies had a targeted
bonus was up to 27% of his base salary predicated on the level of
attainment of the following targets: achievement of the Company's overall
sales goals (25%), achievement of sales of
a certain product (10%), maintaining gross profit of 46%
or above for manufactured products (20%), obtain target market share for
Sun Pharma products (20%) and the balance (25%) based on individual
development goals and at the discretion of our Chief Executive
Officer. The
target allocated for achievement of sales of a certain product was set at
a very high threshold. While there was no assurance of
its success, we believed that a substantial part of the bonus for this
parameter would be earned based on his motivated performance, but that
extraordinary efforts would be necessary to achieve the entire bonus for
such parameter.
|
|
|
●
|
Our
Senior Vice President - Regulatory had a targeted bonus of up to 27% of
his base salary, predicated on the level of attainment of the following
targets: submit all ANDAs in electronic format (20%), improve HIPAA
program and trainings (10%), develop comprehensive safety manual (10%),
review and revise adverse drug effects reporting procedures (25%),
evaluate and determine solutions necessary for electronic DEA processing
(15%), and the balance (20%) based on individual development goals and at
the discretion of our Chief Executive Officer.
|
As a
result of the Company’s overall performance in Fiscal 2009, the Compensation
Committee, in its discretion, determined that no cash bonuses be paid to the
named executive officers set forth above.
Long-Term
Incentives
Long-term
incentives are used to balance the short-term focus of the annual bonus program
with performance over multi-year periods. Stock grants and option grants help to
align the interests of our employees with those of our
stockholders.
We
believe that grants of equity-based compensation:
|
|
•
|
Enhance
the link between the creation of stockholder value and long-term executive
incentive compensation;
|
|
|
•
|
Provide
focus, motivation and retention incentive;
and
|
|
|
•
|
Provide
competitive levels of total
compensation.
|
We made
limited option grants in Fiscal 2009 to certain executive officers, as reflected
in the tables below. The subcommittee of the Compensation Committee
(comprised only of independent directors) received recommendations from the
Chief Executive Officer, based on the Chief Executive Officer’s subjective
judgment of an executive officer’s performance, of the appropriate number of
options to be granted to an executive officer other than the Chief Executive
Officer, and the subcommittee makes the final determination of the grants to all
executive officers, including the Chief Executive Officer. The
employment agreement of the then Chief Executive Officer required that he be
granted options to purchase no less than 40,000 shares of common stock each year
during the term of his agreement based on Company performance in light of
pre-established mutually agreed upon Company goals and objectives. During Fiscal
2009, the subcommittee did not award any options to the Chief Executive Officer.
Options are granted with exercise prices equal to the closing price of our
common stock on the day immediately preceding the date of grant, with pro rata
vesting at the end of each of the following three years. On July 25,
2008, the interim Chief Financial Officer, the Senior Vice President – Business
Strategies and the Senior Vice President – Regulatory were awarded options to
purchase 4,000, 15,000 and 5,000 shares of Common Stock, respectively, by the
subcommittee. On May 2, 2008, pursuant to the terms of his employment
agreement, the Chief Executive Officer was awarded 10,000 shares of our common
stock.
Treatment
of Dividends
We have
not historically paid cash dividends.
Benefits
In
addition to cash and equity compensation programs, executive officers
participate in the retirement, health and welfare benefit programs generally
available to other employees. In a few limited circumstances, we provide other
benefits to certain executive officers, such as car allowances, disability and
life insurance premiums, as set forth in the tables below.
All
executive officers are eligible to participate in the company’s 401(k) plan on
the same basis as our other employees. With the exception of those employees
deemed “highly compensated,” eligible employees are permitted to defer between
1% and 90% of their salary on a pre-tax basis through bi-weekly payroll
deductions. The company matches $0.50 of each $1.00 of each employee’s
contribution up to the first 4% of his or her salary.
Compensation
Committee Interlocks and Insider Participation
As noted,
Mr. Dilip S. Shanghvi is the Chairman of our Compensation Committee and the
Chairman of the Board of Caraco, a non-executive position. Mr.
Shanghvi is also the Chairman and Managing Director of Sun Pharma. As
disclosed above, Sun Pharma and its affiliates engage in a number of
transactions with Caraco. See “Transactions with Directors, Executive
Officers, and certain Beneficial Holders of Caraco” above.
Summary
Compensation Table
The
following table summarizes the total compensation paid to or earned by our Chief
Executive Officer, Interim Chief Financial Officer and our two most highly
compensated executive officers whose total compensation for Fiscal 2009 exceeded
$100,000. For additional information on the compensation summarized
below and other benefits, please refer to “Compensation Discussion and
Analysis,” above.
2009
SUMMARY COMPENSATION TABLE
| Name and Principal |
Stock
Awards
|
Option
Awards
|
All
Other Compensation
|
Total
|
||||||||||||||||||||||
|
Position
|
Year
|
Salary ($)
|
Bonus ($)
|
($)
(1)
|
($)
(2)
|
($)
(3)
|
($)
|
|||||||||||||||||||
|
Daniel
H. Movens –
|
2009
|
429,936 | - | 179,838 | 153,552 | 1,500 | 764,826 | |||||||||||||||||||
|
Chief
Executive Officer (4)
|
2008
|
427,596 | 150,478 | 119,250 | 176,894 | 1,500 | 875,718 | |||||||||||||||||||
|
2007
|
405,600 | 200,772 | 119,250 | 86,727 | 1,500 | 813,849 | ||||||||||||||||||||
|
Mukul
Rathi – Interim
|
2009
|
111,163 | - | - | 7,732 | 8,616 | 127,511 | |||||||||||||||||||
|
Chief
Financial Officer–
|
2008
|
88,335 | 9,945 | - | 2,895 | 7,200 | 108,375 | |||||||||||||||||||
|
2007
|
78,231 | 11,399 | - | 1,930 | 1,200 | 92,760 | ||||||||||||||||||||
|
Gurpartap
Singh Sachdeva
|
2009
|
242,688 | - | - | 18,140 | 13,116 | 273,944 | |||||||||||||||||||
|
–
Senior Vice President
|
2008
|
224,345 | 51,660 | - | - | 11,288 | 287,293 | |||||||||||||||||||
|
–Business
Strategies
|
2007
|
186,030 | 36,392 | - | 650 | 7,128 | 230,200 | |||||||||||||||||||
|
Robert
Kurkiewicz -
|
2009
|
167,834 | - | - | 6,047 | 8.839 | 182,720 | |||||||||||||||||||
|
Senior
Vice President
|
2008
|
161,432 | 35,216 | - | - | 9,314 | 205,962 | |||||||||||||||||||
|
-
Regulatory
|
2007
|
156,818 | 37,578 | - | 650 | 6,245 | 201,291 | |||||||||||||||||||
|
(1)
|
The
amounts reflect the dollar amount recognized for financial statement
reporting purposes for the years ended March 31, 2009, 2008 and 2007,
respectively, in accordance with Statement of Financial Accounting
Standards No. 123(R),
Share-Based Payment (“SFAS No. 123(R)”) of stock
awards and thus include amounts from a stock award of 10,000 shares on May
2, 2008 which vested immediately and 45,000 shares of common stock granted
on May 2, 2005 and which vested at a rate of 15,000 shares on each
anniversary date until fully vested on May 2, 2008. Disclosure of the
assumptions used in the calculation of these amounts are included in note
7 to our audited financial statements, included in our Annual Report on
Form 10-K for the year ended March 31,
2009.
|
|
(2)
|
The
amounts reflect the dollar amount recognized for financial statement
reporting purposes for the years ended March 31, 2009, 2008 and 2007,
respectively, in accordance with SFAS No. 123(R) of stock options
granted under our 2008 Equity Participation Plan and our 1999 Equity
Participation Plan and thus may include amounts from awards granted in and
prior to 2009, 2008 and 2007. We calculated the fair value of
each option award on the date of grant using the Black-Scholes option
pricing model. Disclosure of the assumptions used for grants
are included in footnote 8 to the Notes to financial statements included
in our Annual Report on Form 10-K for the year ended March 31,
2009.
|
|
(3)
|
The
amount shown reflects for each executive officer, other than Mr. Movens,
matching contributions to 401(k) and a car allowance, The
amount shown for Mr. Movens reflects a life insurance
premium.
|
|
(4)
|
Resigned
as Chief Executive Officer and Director effective at the close of business
on July 28, 2009.
|
Fiscal
2009 Chief Executive Officer and Executive Officer Compensation
In Fiscal
2009, our Compensation Committee did not increase the base salary of our Chief
Executive Officer from his Fiscal 2008 base salary. Effective Fiscal
2009, the Chief Executive Officer pursuant to delegated authority from the
Compensation Committee, increased the base salaries for Gurpartap Singh
Sachdeva, Senior Vice President – Business Strategies, Robert Kurkiewicz, Senior
Vice President – Regulatory and Mukul Rathi, interim Chief Financial Officer as
follows: Gurpartap Singh Sachdeva from $225,096 to $243,104; Robert
Kurkiewicz from $161,522 to $167,983 and Mukul Rathi from $88,400 to
$110,000. In light of the Company’s overall performance, no bonuses
were awarded in Fiscal 2009 to the Chief Executive Officer or any of
the other named executive officers. See “Compensation of Executive
Officers – Components of Compensation – Executive Officers” for additional
details.
Grants
of Plan-Based Awards
We
generally award stock options and/or stock grants under our 2008 Equity
Participation Plan. Prior to the adoption of the 2008 Equity
Participation Plan, options and/or stock grants were awarded under our 1999
Equity Participation Plan. The subcommittee of non-employee directors of the
Compensation Committee determines the options to be awarded to the Chief
Executive Officer and our other executive officers. Under our Chief
Executive Officer’s employment agreement, he is entitled to receive during each
year of his term of employment, options to purchase no less than 40,000 shares
of common stock based on the Company’s performance in light of pre-established
mutually agreed upon Company objectives. During Fiscal 2009, no
options were granted to the Chief Executive Officer. The subcommittee
receives recommendations from the Chief Executive Officer, based on the Chief
Executive Officer’s subjective judgment of an executive officer’s performance,
of the appropriate number of options to be granted to an executive officer other
than the Chief Executive Officer. During Fiscal 2009, options were
granted to the other named executive officers as set forth below.
The
following table summarizes all grants of plan-based awards during the years
ended March 31, 2009, 2008 and 2007, respectively, to all named executive
officers. For additional information on the plan-based award grants
summarized below, please refer to “Compensation of Executive Officers –
Components of Compensation – Executive Officers” above.
| Name |
Grant
Date
|
All
Other Option Awards: Number of Securities Underlying Options
(#)
|
Exercise
or Base Price of Option Awards
($
/ Sh)
|
Grant
Date Fair Value
($)
1)
|
|||||||||
|
Daniel
H. Movens – 2008
|
8/09/2007
|
40,000 | 13.82 | 291,288 | |||||||||
|
Daniel
H. Movens - 2007
|
7/11/2006
|
40,000 | 9.03 | 156,108 | |||||||||
|
Mukul
Rathi - 2009
|
7/25/2008
|
4,000 | 15.57 | 19,349 | |||||||||
|
Mukul
Rathi – 2007
|
7/11/2006
|
3,000 | 9.03 | 8,684 | |||||||||
|
Gurpartap
Singh Sachdeva - 2009
|
7/25/2008
|
15,000 | 15.57 | 72,559 | |||||||||
|
Robert
Kurkiewicz - 2009
|
7/25/2008
|
5,000 | 15.57 | 24,186 | |||||||||
|
(1)
|
The
amount shown in this column represents full grant date fair
value. Value of stock granted is based on “grant date present
value” using a Black-Scholes option pricing model using
weighted average assumptions at grant date. Disclosure of the
assumptions used for grants in Fiscal 2009, 2008
and 2007 are included in footnote 8 to the Notes to the
financial statement included in our Annual Report on Form 10-K for the
year ended March 31, 2009.
|
Outstanding
Equity Awards at Fiscal Year-End
The
following table provides information as of March 31, 2009 regarding unexercised
options and stock that has not vested which are outstanding as of March 31,
2009.
|
Option
Awards
|
Stock
Awards
|
||||||||||||||||||||
|
Name
|
Number
of Securities Underlying Unexercised Options
(#)
Exercisable
|
Number
of Securities Underlying Unexercised Options
(#)(1)
Unexercisable
|
Option
Exercise Price
($)
|
Option
Expiration Date
|
Number
of Shares or Units of Stock That Have Not Vested
(#)
|
Market
Value of Shares or Units of Stock That Have Not Vested
($)
|
|||||||||||||||
|
Daniel
Movens
|
|||||||||||||||||||||
|
5/02/05
|
40,000 | - | 8.31 |
5/2/2011
|
- | - | (2) | ||||||||||||||
|
7/11/06
|
26,667 | 13,333 | 9.03 |
7/11/2012
|
- | - | |||||||||||||||
|
8/09/07
|
13,333 | 26,667 | 13.82 |
8/19/2013
|
- | - | |||||||||||||||
|
Mukul
Rathi,
|
|||||||||||||||||||||
|
7/11/06
|
2,000 | 1,000 | 9.03 |
7/11/2012
|
- | - | |||||||||||||||
|
7/25/08
|
0 | 4,000 | 15.57 |
7/25/2014
|
- | - | |||||||||||||||
|
Gurpartap
Singh Sachdeva
|
|||||||||||||||||||||
|
7/25/08
|
0 | 15,000 | 15.57 |
7/25/2014
|
- | - | |||||||||||||||
|
Robert
Kurkiewicz
|
|||||||||||||||||||||
|
7/25/08
|
0 | 5,000 | 15.57 |
7/25/2014
|
- | - | |||||||||||||||
_____________________________
|
(1)
|
One-third
of stock options vest on each anniversary
date.
|
Option
Exercises and Stock Vested
The following table sets forth the
options exercised by the named executive officers, and the stock of the named
executive officers which vested, during the Fiscal years ended March 31, 2009,
2008 and 2007, respectively.
|
Option
Awards
|
Stock
Awards
|
||||||||||||||||
|
Name
|
Number
of Shares Acquired on
Exercise
(#)
|
Value
Realized on Exercise
($)
(1)
|
Number
of Shares
Acquired
on Vesting
#
|
Value
Realized on Vesting
$
(2)
|
|||||||||||||
|
Daniel
H. Movens
|
2009
|
- | - | 25,000 | 424,750 | ||||||||||||
|
Daniel
H. Movens
|
2008
|
- | - | 15,000 | 217,800 | ||||||||||||
|
Daniel
H. Movens
|
2007
|
- | - | 15,000 | 184,650 | ||||||||||||
|
Mukul
Rathi
|
2009
|
- | - | - | - | ||||||||||||
|
Mukul
Rathi
|
2008
|
- | - | - | - | ||||||||||||
|
Mukul
Rathi
|
2007
|
- | - | - | - | ||||||||||||
|
Gurpartap
Singh Sachdeva
|
2009
|
- | - | - | - | ||||||||||||
|
Gurpartap
Singh Sachdeva
|
2008
|
- | - | - | - | ||||||||||||
|
Gurpartap
Singh Sachdeva
|
2007
|
2,000 | 21,280 | - | - | ||||||||||||
|
Robert
Kurkiewicz
|
2009
|
- | - | - | - | ||||||||||||
|
Robert
Kurkiewicz
|
2008
|
10,000 | 139,000 | - | - | ||||||||||||
|
Robert
Kurkiewicz
|
2007
|
- | - | - | - | ||||||||||||
|
(1)
|
The
value realized on exercise is the difference between the closing price of
the Company’s common stock at the time of exercise and the option exercise
price times the number of shares acquired on
exercise.
|
|
(2)
|
The
value realized on vesting is obtained by multiplying the number of shares
of stock which has vested during the applicable years ended March 31,
2009, 2008 and 2007 by the market value of the Company’s common stock on
the vesting date.
|
Employment
Agreements and Potential Payments Upon Termination or
Change-in-Control
As
previously disclosed, Jitendra N. Doshi was appointed interim Chief Executive
Officer of the Company at the close of business on July 28, 2009. On
August 31, 2009, Mr. Doshi entered into an employment agreement with the
Company.
The
employment agreement provides Mr. Doshi, as interim Chief Executive Officer,
with a salary at the rate of $275,000 annually, which, to the extent applicable,
may be reviewed annually and adjusted, a car allowance of $600.00 per month and
such employee benefits as are maintained or adopted by the Company for all
employees. The employment agreement is for a term of one (1) year,
commencing effective as of July 28, 2009, and automatically renews for
successive one-year periods, however, the agreement may be terminated at any
time by the Company or Mr. Doshi with or without cause or notice.
If Caraco
terminates Mr. Doshi for just cause or if Mr. Doshi terminates the employment
agreement without cause or in the event of the death of Mr. Doshi, he shall be
entitled to his base salary and benefits earned by him prior to such termination
or date of death. For purposes of the agreement, ‘just cause’ means
dishonesty, or refusal or failure by Mr. Doshi to faithfully or diligently
perform his duties, including the failure to adhere to the policies of the
Board. In the event Caraco terminates Mr. Doshi without just cause or
if Mr. Doshi terminates for cause not attributable to him (meaning Caraco
failing to make any payment of base salary to him within 30 days after such
payment is due), he will receive monthly base salary payments and the Company
shall continue premium payments for health insurance for six (6) months from the
date of termination, and any stock options that would become available for
exercise at the end of the year during which such termination occurred shall
immediately vest.
Daniel H.
Movens, who was the Chief Executive Officer of Caraco until his resignation
effective at the close of business on July 28, 2009, entered into an employment
agreement with Caraco dated as of May 2, 2005 (the “effective date”). Under the
employment agreement, Mr. Movens agreed to serve as Chief Executive Officer of
the Company for period of thirty-six (36) calendar months which would
automatically renew at the end of thirty-six (36) months. Each party
may terminate the agreement upon ninety (90) days written notice to the other
party. The agreement provides Mr. Movens with: a base salary during
the first year of the agreement of $390,000 (to be reviewed annually by the
Compensation Committee and adjusted accordingly, in its discretion), a bonus of
up to fifty (50%) percent of the base compensation (with twenty-five (25%)
percent of the base compensation guaranteed only for the first year), and stock
options for 40,000 shares upon the effective date at the fair market value of
the common stock on the day immediately preceding the effective date and stock
options for not less than 40,000 shares of the Company annually thereafter based
on Company performance in light of pre-established mutually agreed upon Company
goals and objectives (all such options to vest over a period of three years from
the date of their respective grants), a stock grant on the effective date of
45,000 shares of the Company’s common stock (to vest over a period of three (3)
years), and a stock grant of an additional 10,000 shares upon the renewal of the
employment agreement. In addition, the Company provided for the
reimbursement to Mr. Movens of his reasonable relocation expenses up to
$50,000.
On July
28, 2009, Mr. Movens entered into a Separation Agreement and Release of all
Claims (“Separation Agreement”) pursuant to which he resigned as Chief Executive
Officer and a Director of the Company. Under the Separation
Agreement, Mr. Movens received a separation payment of $870,621 (one and
one-half times his highest annual base and last earned bonus), the continuation
of his health, vision and dental insurance for twelve months and the immediate
vesting of his outstanding stock options and stock grants. In
addition, Mr. Movens is bound by the confidentiality provisions of his
employment agreement and by his Confidentiality and Non-Competition Agreement,
pursuant to which Mr. Movens agrees not to solicit any customer of the Company
for business in competition with the Company, or solicit for employment any
other employee of the Company, for a period of two (2) years following his
termination. In addition, for a period of twelve (12) months
following the termination of his employment, Mr. Movens agrees not to engage in
any activity within North America which is competitive in any material respect
with the business of the Company, including generic pharmaceutical manufacturing
and marketing, but excluding wholesale distribution. In addition, for
a period of twelve (12) months following termination of his employment, Mr.
Movens agrees that he will not perform services for any business or
organization, whether as an employee, consultant, advisor, independent
contractor, or otherwise, which engages in any activity within North America
that is competitive in any material respect with the business conducted by the
Company, including any business engaged in generic pharmaceutical manufacturing
and marketing and any other business in which the Company generates more than
ten (10%) percent of its gross revenues.
Robert
Kurkiewicz, the Senior Vice President - Regulatory, entered into a five-year
employment agreement on November 22, 1993 which was amended on January 1, 1999
to extend the term until January 1, 2003 and which was further amended on August
30, 2002 to extend the term until December 31, 2007. The agreement,
as amended, provides Mr. Kurkiewicz with a salary of $129,800 per year and
provides for a car allowance of $380.00 per month. The agreement
provides that at the end of the term, it is renewable for successive one-year
terms. In the event that Caraco terminates Mr. Kurkiewicz for ‘cause’
(as defined in the employment agreement), he is entitled to the base salary and
benefits earned by him prior to the date of termination. In the event
that Caraco terminates the agreement without cause or Mr. Kurkiewicz terminates
the agreement for cause not attributable to him (meaning Caraco failing to make
any payment of base salary to him within 30 days after such payment is due), Mr.
Kurkiewicz is entitled to receive monthly base salary payments and his premium
payments for health insurance benefits for six (6) months from the date of
termination. In addition, any stock options that would become
available for exercise at the end of the year during which such termination
occurred shall immediately vest. In August 2005, the Compensation
Committee increased Mr. Kurkiewicz’s salary to $152,250 annually. If
Mr. Kurkiewicz was terminated without cause or he terminates for cause, as set
forth above, as of March 31, 2009, he would have received payment (including the
value of the benefits and the vested options and stock (assuming the closing
stock price on March 31, 2009) of $87,580.
Gurpartap
Singh Sachdeva, the Senior Vice President - Business Strategies, entered into an
employment agreement with Caraco dated February 1, 2005. The
employment agreement provides Mr. Sachdeva with a salary at the rate of $135,000
annually, which may be reviewed and adjusted, and a car allowance of $380.00 per
month. The employment agreement is for a term of five (5) years,
commencing on February 1, 2005. The agreement automatically renews
for successive one-year periods unless terminated by Caraco or Mr. Sachdeva upon
ninety (90) days notice. In the event of the death or Disability (as
such term is defined in the employment agreement) or if Caraco terminates Mr.
Sachdeva for just cause (as such term is defined in the employment agreement),
Mr. Sachdeva shall be entitled to his base salary and to benefits earned by him
prior to the date of death, Disability or termination for just cause,
respectively. In the event Caraco terminates Mr. Sachdeva without
cause or if Mr. Sachdeva terminates for cause not attributable to him (meaning
Caraco failing to make any payment of base salary to him within 30 days after
such payment is due), he will receive base salary payments and his premium
payments for health insurance benefits for six (6) months from the date of
termination. In addition, any stock options that would become
available for exercise at the end of the year during which such termination
occurred shall immediately vest. If Mr. Sachdeva was terminated
without cause or he terminates for cause, as set forth above, as of March 31,
2009, he would have received payment (including the value of the benefits and
the vested options and stock (assuming the closing stock price on March 31,
2009) of $126,354.
Change
in Control Arrangements
Under our
2008 Equity Participation Plan, options granted under that plan will become
fully exercisable following certain changes in control of our Company, such
as:
A person,
other than Sun Pharma, becomes the owner of a majority of the outstanding shares
of our company;
A public
announcement is made of a tender or exchange offer by any person, other than Sun
Pharma, for 50% or more of the outstanding shares of our company;
The
shareholders of our company approve a merger or consolidation with any other
corporation or entity, unless, following the merger, the shares outstanding
immediately before the merger continue to represent a majority of the
outstanding shares of the surviving entity immediately following the
merger.
DIRECTOR COMPENSATION
Directors
who are employees of Caraco or who are directors and/or employees of Sun Pharma
and its affiliates do not receive additional compensation for their service on
the Board of Directors and its committees. During 2009, all other
directors, the non-employee directors, received an annual retainer of $12,000
and meeting attendance fees of $1,500 per each Board of Directors meeting and
each committee meeting attended in person and $750 per each Board of Directors
meeting and each committee meeting attended via
teleconference. During 2009, the Chairman of the Audit Committee and
the Chairman of the Independent Committee received, in addition to the other
fees mentioned, an additional $500 for each meeting. No additional
committee fees are paid if the committee meets on the same day as the Board
meets. All
directors are entitled to reimbursement for reasonable travel and lodging
expenses incurred in attending meetings. With respect to the Special
Litigation Committee referenced under “Board of Directors and its
Committees –Committees of the Board,” the Board has agreed to compensate Mr.
Bell for these additional director services in the amount of $200 per
hour. Mr. Bell will not receive any meeting attendance fees with
respect to his service on the Special Litigation Committee. The
following table shows the value of all cash and equity-based compensation paid
to the non-employee members of our Board of Directors during the year ended
March 31, 2009.
|
Name
|
Fees
Earned or
Paid
in Cash
($)
|
Option
Awards
($)
(1)
|
Total
($)
|
|||||||||
|
John
D. Crissman (2)
|
17,250 | 10,220 | 27,470 | |||||||||
|
Timothy
S. Manney
|
20,000 | 8,384 | 28,384 | |||||||||
|
Madhava
Reddy
|
12,750 | 10,220 | 22,970 | |||||||||
|
Georges
Ugeux (3)
|
15,000 | 8,389 | 23,389 | |||||||||
|
|
(1)
|
Represents
the grant date fair value of such options computed in accordance with FAS
123R. Disclosure of the assumptions used for grants for the year ended
March 31, 2009 are included in footnote 8 to the Notes to financial
statements included in our Annual Report on From 10-K for the year ended
March 31, 2009.
|
|
|
(2)
|
Dr.
Crissman did not stand for re-election at the 2009 Annual Meeting of
Stockholders and is no longer a Director of the
Company.
|
|
|
(3)
|
Mr.
Ugeux resigned as a Director of the Company on September 20,
2009.
|
RELATIONSHIP WITH INDEPENDENT AUDITORS
The Audit
Committee has appointed Rehmann Robson as the Company’s independent registered
public accounting firm to audit the Company’s financial statements for the
Fiscal year ending March 31, 2010. A representative of
Rehmann Robson is not expected to be present at the Special
Meeting.
Audit
and Non-Audit Fees
Aggregate
fees for professional services rendered for Caraco by Rehmann Robson for the
Fiscal years ended March 31, 2009 and 2008 are set forth below. The aggregate
fees included in the Audit Fee category are fees billed for the audit of Caraco’s
Fiscal financial statements and review of quarterly financial
statements and statutory and regulatory filings or engagements. The aggregate
fees included in each of the other categories are fees billed in the Fiscal
years.
|
Fiscal
2009
|
Fiscal
2008
|
|||||||
|
Audit
Fees
|
$ | 264,000 | $ | 227,812 | ||||
|
Audit
Related Fees
|
- | - | ||||||
|
Tax
Fees
|
$ | 76,315 | $ | 141,690 | ||||
|
All
Other Fees
|
$ | 20,175 | $ | 7,525 | ||||
|
Total
|
$ | 360,490 | $ | 377,027 | ||||
Audit Fees for the Fiscal
years ended March 31, 2009 and 2008 were for professional services rendered for
the audits of the financial statements of Caraco, quarterly review of the
financial statements included in Caraco’s Quarterly Reports on Form 10-Q, or
services that are normally provided by Rehmann Robson in connection with
statutory and regulatory filings or engagements for such years, including
Rehmann’s Robson’s audit of management’s assessment of internal control over
financial reporting as of March 31, 2009 and March 31, 2008.
Tax Fees for the Fiscal years
ended March 31, 2009 and 2008 were for professional services rendered by Rehmann
Robson for services related to tax compliance, tax advice and tax
planning.
All Other Fees for the Fiscal
years ended March 31, 2009 and 2008 were for assistance on SEC reporting
requirements.
None of
the services described above was approved by the Audit Committee under the de minimus exception
provided by Rule 2-01(c)(7)(i)(C) under Regulation S-X.
Policy
on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of
Independent Auditors
Pursuant
to its charter, the Audit Committee pre-approves all audit and non-audit
services provided by the independent auditors prior to the engagement of the
independent auditors with respect to such services.
SHAREHOLDERS
OF RECORD AS SEPTEMBER 21, 2009 ARE ENTITLED TO RECEIVE A COPY WITHOUT CHARGE OF
THE COMPANY’S FISCAL 2009 ANNUAL REPORT TO THE SEC ON FORM 10-K. SHAREHOLDERS
WHO WISH TO RECEIVE A COPY OF THIS REPORT SHOULD WRITE TO DONNA GRIFFITH,
DIRECTOR, HUMAN RESOURCES, CARACO PHARMACEUTICAL LABORATORIES, LTD, 1150 ELIJAH
MCCOY DRIVE, DETROIT, MICHIGAN 48202.
|
Jitendra
N. Doshi
|
|
|
Chief
Executive Officer
|
October
__, 2009
APPENDIX A
AMENDMENT
TO AMENDED AND RESTATED ARTICLES OF INCORPORATION OF CARACO PHARMACEUTICAL
LABORATORIES, LTD.
Article
VI, paragraph 4 of the Amended and Restated Articles of Incorporation is
proposed to be revised to read as follows
| “4. Subject to the rights of the holders of any series of Preferred Shares then outstanding, newly created directorships resulting from any increase in the authorized number of directors and any vacancies on the Board resulting from death, resignation, retirement, disqualification, removal from office or other cause shall be filled by a majority vote of the remaining directors then in office, though less than a quorum, and/or by a vote to ratify or elect by a majority of the shares present in person or represented by proxy and voting on such ratification or election, and directors so chosen shall hold office for a term expiring at the annual meeting of shareholders at which the term of office of the class to which they have been elected expires or until their successors have been duly elected and qualified. No decrease in the number of directors constituting the Board shall shorten the term of any incumbent director.” |
SPECIAL
MEETING OF SHAREHOLDERS OF
CARACO
PHARMACEUTICAL LABORATORIES, LTD.
October
26, 2009
NOTICE OF INTERNET
AVAILABILITY OF PROXY MATERIAL:
The
Notice of Annual Meeting of Shareholders and Proxy Statement
are
available at https://materials.proxyvote.com/14075T
Please
date, sign and mail
your
proxy card in the
envelope
provided as soon
as
possible.
|
↓
|
↓
|
|
|
Please
detach along perforated line and mail in the
envelope provided.
|
|
THE
BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE AMENDMENT TO THE AMENDED
AND RESTATED ARTICLES OF INCORPORATION AND “FOR” THE
DIRECTOR
PLEASE
SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE
MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE S
|
|
1.
To approve the amendment to Article VI, paragraph 4 of the
Company’s Amended and Restated Articles of Incorporation to permit
vacancies on the Board of Directors to also be filled by a vote of the
Company’s shareholders.
|
FOR
£
|
AGAINST
£ |
ABSTAIN
£
|
|
2.
|
The
ratification and election of one director.
|
|
|
□ FOR
F. FOLSOM BELL
|
|||||||
|
|
|||||||
|
□ WITHHOLD
AUTHORITY
FOR F. FOLSOM
BELL |
|||||||
| 3. |
To transact
such other business as may properly come before the Special Meeting or any
adjournment(s) or continuation thereof. |
||||||
|
Please
be sure to sign and date this Proxy.
|
|||||||
|
TO
INCLUDE ANY COMMENTS, USE THE COMMENTS BOX ON THE REVERSESIDE
OF THIS CARD.
|
|||||||
| To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method. | |||||||
|
Signature
of Shareholder
|
Date:
|
Signature
of Shareholder
|
Date
|
|
NOTE:
|
Please
sign exactly as your name or names appear on the Proxy. When shares
are held jointly, each holder should sign. When signing as executor,
administrator, attorney, trustee or guardian, please give full title as
such. If the signer is a corporation, please sign full corporate
name by duly authorized officer, giving full title as such. If
signer is a partnership, please sign in partnership name by authorized
person. O
|
CARACO
PHARMACEUTICAL LABORATORIES, LTD.
This
Proxy is Solicited by the Board of Directors of Caraco Pharmaceutical
Laboratories, Ltd.
The
undersigned hereby appoints Robert Kurkiewicz and Donna Griffith, or either of
them, each with power of substitution, to act as proxies for the undersigned, to
represent the undersigned at the Special Meeting of Shareholders (“Special
Meeting”) of Caraco Pharmaceutical Laboratories, Ltd. (“Caraco”) to be held at
the executive offices of Caraco at 1150 Elijah McCoy Drive on Monday, October
26, 2009 at 11:00 a.m., Eastern Daylight Saving Time, and at any adjournment(s)
thereof, and to vote the number of shares the undersigned would be entitled to
vote if personally present on all matters coming before the Special Meeting,
including the business identified on this Proxy and described in the Notice of
Special Meeting of Shareholders and Proxy Statement dated October __, 2009
(“2009 Proxy Statement”).
This
revocable Proxy, when properly executed, will be voted in the manner directed by
the undersigned shareholder. If no direction is made on an
executed Proxy, this Proxy will be voted by the proxies “FOR” the amendment to
Caraco’s Amended and Restated Articles of Incorporation as set forth in Proposal
1 and “FOR” the ratification and election of F. Folsom Bell as a director
as set forth in Proposal 2. Discretionary authority is
conferred by this Proxy with respect to certain matters as described in the 2009
Proxy Statement.
The
undersigned acknowledges receipt of the 2009 Proxy
Statement. Regardless of whether you plan to attend the Special
Meeting, you can be sure your shares are represented at the Special Meeting by
signing, dating and returning your proxy card in the enclosed
envelope.
PLEASE
VOTE, DATE, AND SIGN ON REVERSE AND RETURN PROMPTLY IN THE ENCLOSED
ENVELOPE.
(Continued
and to be signed on the reverse side)
|
COMMENTS:
|